ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2016
When the Minimal Becomes Measurable.
Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Defining and managing high-risk acute myeloid leukemia (AML) in 2026.Annals of hematology · 2026Review
- Fludarabine melphalan reduced intensity conditioning vs radiation-based myeloablative conditioning in patients undergoing allogeneic transplantation for acute myeloid leukemia with measurable residual disease.Bone marrow transplantation · 2025Article
- Test Then Erase? Current Status and Future Opportunities for Measurable Residual Disease Testing in Acute Myeloid Leukemia.Acta haematologica · 2024Review
- Measurable Residual Disease (MRD) as a Surrogate Efficacy-Response Biomarker in AML.International journal of molecular sciences · 2023Review
- Measurable Residual Disease and Clonal Evolution in Acute Myeloid Leukemia from Diagnosis to Post-Transplant Follow-Up: The Role of Next-Generation Sequencing.Biomedicines · 2023Review
- Maintenance therapy for AML after allogeneic HCT.Frontiers in oncology · 2022Review
- Use of Measurable Residual Disease to Evolve Transplant Policy in Acute Myeloid Leukemia: A 20-Year Monocentric Observation.Cancers · 2021Article
- Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2020Article
- MRD evaluation of AML in clinical practice: are we there yet?Hematology. American Society of Hematology. Education Program · 2019Review
- Measurable Residual Disease at Induction Redefines Partial Response in Acute Myeloid Leukemia and Stratifies Outcomes in Patients at Standard Risk Without NPM1 Mutations.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2018Article
- Personalizing initial therapy in acute myeloid leukemia: incorporating novel agents into clinical practice.Therapeutic advances in hematology · 2018Review
- Molecular Measurable Residual Disease Testing of Blood During AML Cytotoxic Therapy for Early Prediction of Clinical Response.Frontiers in oncology · 2018Article
- The Prognostic Significance of Measurable ("Minimal") Residual Disease in Acute Myeloid Leukemia.Current hematologic malignancy reports · 2017Review
- Technical Advances in the Measurement of Residual Disease in Acute Myeloid Leukemia.Journal of clinical medicine · 2017Review
- Review
- Bone marrow evaluation for diagnosis and monitoring of acute myeloid leukemia.Blood reviews · 2017Review
- Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2016Article
- Measurable Residual Disease Assessment as a Surrogate Marker in New Drug Development in Acute Myeloid Leukemia.Cancer journal (Sudbury, Mass.)Article
Corrections and comments
- Commented on by
- Commented on by
- Comment on
Authors and funding
7 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Identifiers
27185839What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.